Spruce Biosciences (SPRB): Analyst Targets Suggest Potential +200% Upside to $150

Key Takeaways

• The central $150 stock price target reflects the rounded average of recent analyst price targets for Spruce Biosciences, Inc. (SPRB), a clinical-stage biopharmaceutical company.
• The stock recently traded near $49, so a move to $150 would imply upside of roughly 200% — a substantial gain.
• Individual analyst price targets range widely from about $104 to $230, highlighting differing views on clinical and financing outcomes.
• Supporting elements include a "Strong Buy" leaning among analysts, a cash-rich balance sheet relative to market value, and notable short interest that could add volatility.
• Key risks involve ongoing net losses, a recent earnings miss, high volatility with beta above 3, and reliance on future clinical and regulatory milestones.
• For additional context, review Major News, Today's Price Move, the Forecast, and Earnings pages.
• One can also check Trending AI Robots to see how automated strategies are navigating similar situations.

Analyst Price Targets and the Consensus Picture

Spruce Biosciences operates as a development-stage drugmaker with relatively limited but active analyst coverage. Targets vary widely because each firm applies different assumptions about clinical success probabilities and potential future dilution. Looking at roughly nine to ten recent, attributed price targets, the spread runs from around $104 at the low end to $230 at the high end — a gap of about $126 that points to real differences in outlook rather than a narrow consensus.

Recent updates show the mix in action. Lake Street started coverage with a Buy rating and $149 target in September 2026, Citizens reiterated Market Outperform with a $144 target that same month, and Craig-Hallum held a Buy at $140. On the higher side, Oppenheimer maintains a $230 target while B. Riley sits at $160. More cautious calls include Leerink Partners trimming to $120 and H.C. Wainwright adjusting at least one target near $104. The average of these recent figures lands in the upper $140s, rounding to the $150 central target referenced here.

This $150 level represents a calculated average of verified targets rather than an official consensus figure, so it should be considered alongside the broad low-to-high range.

Current Market Position and the Road to the Target

With SPRB trading around $49 — within a 52-week range of roughly $38 to $129 — reaching $150 would require a gain of about 200%. That represents a very large move and would place the stock well above its prior 52-week high.

The path would likely depend on company-specific catalysts more than broader sector trends. Spruce is a micro-cap with a market capitalization near $140 million and essentially no product revenue, so valuation hinges on the perceived odds that its lead program, tildacerfont, can navigate clinical and regulatory steps. A single positive data readout, partnership payment, or financing event has driven outsized moves in the past, consistent with the stock’s beta of roughly 3.5. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Factors That Could Support a Move Toward the Target

Several elements could underpin upside potential. The company holds a net cash position of roughly $80 million, or more than $27 per share — more than half the current share price — which reduces near-term dilution risk compared with many peers. Most covering analysts maintain Buy or equivalent ratings, indicating the research community sees value well above current levels. Heavy short interest of roughly 18% of shares outstanding could amplify upward moves if positive news triggers short covering. Any clinical or regulatory progress on tildacerfont or an expanded partnership could also shift the market’s probability assessment of the pipeline.

Obstacles That Could Keep the Target Out of Reach

The challenges are equally clear. Spruce continues to report significant net losses, and its most recent quarterly result missed expectations, with GAAP EPS of roughly -$8.51 versus a consensus estimate near -$5.76. Development-stage companies often need additional capital, and future share issuance would dilute existing holders. Clinical trials carry a high risk of failure, and a disappointing readout could pressure the stock quickly. The wide analyst range, with some targets below $110, reflects the real possibility that the market assigns a lower value to the pipeline than the most bullish models suggest.

Technical Levels and Market Structure

From a technical perspective, $150 sits above the stock’s prior 52-week high near $129, so there is little established overhead supply between that level and the target. On the downside, the 52-week low near $38 and the 50-day moving average near $48 serve as reference points. The stock’s elevated beta and wide daily ranges point to a thin, volatile tape where large percentage swings are common, so conventional support and resistance levels should be viewed as approximate zones rather than exact lines.

Time Horizon and Key Items to Watch

Analyst price targets generally reflect a research horizon of about 12 months, though individual firms may use shorter or longer windows, and targets for clinical-stage companies often embed assumptions about specific data events. Investors should monitor quarterly earnings and cash burn, any clinical readouts or regulatory updates for tildacerfont, analyst target revisions (which have been frequent and occasionally sharp), and any financing or partnership announcements. Changes in short interest and institutional positioning are also worth tracking given the stock’s structure.

Using AI Daily Buy/Sell Signals in Practice

In my own process for following volatile, news-driven names like Spruce Biosciences, Tickeron’s AI Daily Buy/Sell Signals provide a useful additional perspective. The system applies artificial intelligence to scan thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and data-driven analysis. This helps surface opportunities, track positions, and identify trend changes more efficiently than manual review alone.

Final Assessment

The central $150 target — the rounded average of recent analyst price targets — implies roughly 200% upside from a price near $49, a very large move that would require an optimistic clinical and financing scenario. The main supports include the net-cash balance sheet, the predominantly bullish analyst stance, and the potential for short covering on positive catalysts. The principal obstacles remain recurring losses, the recent earnings miss, dilution risk, and the genuine uncertainty reflected in the wide $104-to-$230 target range. The broad disagreement among analysts itself serves as the key signal: this is a high-risk, high-volatility name where outcomes will be driven by data and capital decisions rather than the average target. Investors should watch clinical updates, cash position, analyst revisions, and any new financing before forming conclusions.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Sergey Savastiouk|Expert

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.

Notable companies

Industry description

Market Cap

High and low price notable news

Volume